Inotersen for treating hereditary transthyretin amyloidosis - guidance (HST9)

Source:
National Institute for Health and Care Excellence - NICE
Publication date:
22 May 2019

Abstract

Evidence-based recommendations on inotersen (Tegsedi) for stage 1 and stage 2 polyneuropathy in adults with hereditary transthyretin amyloidosis.

Is this guidance up to date?

Next review: 2022

Commercial arrangement

There is a patient access scheme for inotersen. Contact PASenquiries@akceatx.com or 01932 871862 for details.

Guidance development process

How we develop NICE highly specialised technology guidance